Dijon

• Durvalumab (immunotherapy) maintenance after thoracic chemoradiotherapy (CRT) in frail small cell lung cancer patients whose disease is limi … Ended recruitment
  2024-512224-11-00 4 2023-03-24 Histologically confirmed frail Limited Disease Small Cell Lung Cancer
• PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien … Ended recruitment
  2022-501217-31-00 10 2023-03-09 Hepatocellular carcinoma
• Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized tr … Ended recruitment
  2022-501179-23-00 6 2023-03-08 atopic dermatitis
• An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult P … Ended recruitment
  2024-510995-18-00 1 2023-03-01 Advanced Solid Tumors
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C … Ended recruitment
  2023-505552-22-00 5 2023-02-24 Stage I-III Triple-negative Breast Cancer with residual invasive disea
• A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L … Ended recruitment
  2024-511594-30-00 5 2023-02-23 Relapsed/Refractory Follicular Lymphoma
• Evaluating the superiority of VAsopressin versus NOradrenaline in the management of the renal risk patient undergoing cardiac surgery with e … Ended recruitment
  2022-500419-38-00 5 2022-12-28 vasoplegic syndrome
• Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Ended recruitment
  2024-512915-33-00 5 2022-12-22 Metastatic Colorectal Cancer
• Treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor in mRCC patients that has … Ended recruitment
  2024-514644-93-00 5 2022-12-09 Metastatic renal cell carcinoma (mRCC) with a good or only one adverse
• Study to evaluate the long-term safety of GT005 in participants having macular degeneration that led to geographic atrophy in their eyes and … Ended recruitment
  2024-510946-15-00 9 2022-12-08 Geographic atrophy (GA) secondary to age-related macular degeneration
• RITUX-PLUS 2 : A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of rituximab combined with subcutane … Ended recruitment
  2024-516168-27-00 5 2022-11-10 Adult patients with persistent or chronic immune thrombocytopenia
• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U … Ended recruitment
  2023-505772-30-00 5 2022-11-09 Melanoma
• This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in … Ended recruitment
  2023-505628-67-00 5 2022-10-28 Relapsed and Refractory Follicular Lymphoma
• Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended recruitment
  2024-514480-26-00 4 2022-10-12 Post-menopausal women with localized luminal A breast cancer and consi
• Multicentric randomized phase I / II study to evaluate efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α True Human … Ended recruitment
  2024-517024-20-00 9 2022-09-27 Metastatic colorectal cancer patients
• SPLEMENGO - Multicenter, randomized, phase III, trial assessing the immunogenicity and safety of three meningococal B vaccine strategies amo … Ended recruitment
  2024-513649-35-00 5 2022-09-15 Asplenia
• Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea … Ended recruitment
  2024-514630-21-00 4 2022-08-11 HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
• A Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors Ended recruitment
  2024-513611-28-00 4 2022-07-29 Metastatic Solid Tumors
• A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer ( … Ended recruitment
  2023-509260-25-00 5 2022-07-12 Locally Recurrent Inoperable or Metastatic Triple-negative Breast Canc
• An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered to Patients with Familial Chylomicronemia Syndrome (FCS) Ended recruitment
  2023-509029-29-00 5 2022-06-29 Familial Chylomicronemia Syndrome (FCS)
• A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and n … Ended recruitment
  2024-512799-36-00 3 2022-06-16 head and neck squamous cell carcinoma (HNSCC)
• IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot … Ended recruitment
  2023-510387-13-00 4 2022-05-18 advanced ALK-positive non-small cell lung cancer
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended recruitment
  2023-507131-38-00 5 2022-05-16 Neovascular Age-Related Macular Degeneration (nAMD)
• A phase 1/1b/2 study of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors. Ended recruitment
  2023-504363-17-00 7 2022-05-13 Advanced MTAP-null solid tumors

Showing 529–552 of 813 trials